Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 2019 - GlobeNewswire

Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 2019  GlobeNewswire

Heidelberg, Germany, June 24, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ...



Comments

Popular posts from this blog

Shave your pubic hair if you want, but not at these times

Keto crotch: Is it real and how to treat it